

Docket No.: 0020-5329PUS1

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Haruo SUGIYAMA et al.

Application No.: 10/517,600

Filed: December 13, 2004

For: HLA-A24-RESTRICTED CANCER ANTIGEN

PEPTIDES

Confirmation No.: 4687

Art Unit: 1615

Examiner: Not Yet Assigned

RESPONSE TO NOTICE TO COMPLY

MS Sequence Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

On June 3, 2005 the U.S. Patent and Trademark Office mailed to Applicant's representative a Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures.

The paper copy of the Sequence Listing for the present application filed December 13, 2004, is identical to the computer readable copy of the Sequence Listing attached hereto. The paper copy of the Sequence Listing is also attached again.

Attached is a Petition for Extension of Time.
Attached hereto is the fee transmittal listing the required fees.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for

Application No.: 10/517,600 Docket No.: 0020-5329PUS1

any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Dated: June 24, 2005

Respectfully submitted,

Mark J. Nuell, Ph.D.

Registration No.: 36,623

BIRCH, STEWART, KOLASCH & BIRCH, LLP

8110 Gatehouse Rd Suite 100 East

Falls Church, Virginia 22040-0747

(703) 205-8000

P.O. Box 747

Attorney for Applicant

Attachments: Copy of Notice to Comply

Paper copy and Computer readable form (diskette) of Sequence Listing

PRIORITY DATE

06/12/2002



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.C. Dox 1450 Alexambia, Vignus 22313-1450 www.unplusgov

ATTY. DOCKET NO. FIRST NAMED APPLICANT U.S. APPLICATION NUMBER NO. 0020-5329PUS1 10/517,600 Haruo Sugiyama

INTERNATIONAL APPLICATION NO.

I.A. FILING DATE

06/12/2003

PCT/JP03/07463

02292 **BIRCH STEWART KOLASCH & BIRCH** PO BOX 747 FALLS CHURCH, VA 22040-0747

CONFIRMATION NO. 4687 371 FORMALITIES LETTER *OC000000016176154*

Date Mailed: 06/03/2005

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed

to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice **MUST** be returned with the response.

KAREN M WILLIAMS

Telephone: (703) 308-9140 EXT 213

PART 1 - ATTORNEY/APPLICANT COPY

· · · · · · · · · · · · · · · · · · ·				
U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY, DOCKET NO.		
10/517.600	PCT/JP03/07463	0020-5329PUS1		

FORM PCT/DO/EO/922 (371 Formalities Notice)